BCAT1 and chronic myelogenous leukemia, BCR-ABL1 positive: The use of BCAT1 inhibitors can inhibit the development of the disease, which is of great help for the early diagnosis, intervention and treatment of ML, making targeted therapy of CML a promising solution.